NDT Advance Access published online on June 8, 2004
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh329
© 2004 by European Renal Association - European Dialysis and Transplant Association
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan
* To whom correspondence should be addressed. E-mail: matuhiko{at}sc.itc.keio.ac.jp.
Background. To identify differences between the effects of calcitriol and the calcitriol analogue, maxacalcitol, on parathyroid hormone (PTH) and bone metabolisms, we conducted a randomized prospective multicentre study on patients on chronic haemodialysis. Methods. We randomly assigned 91 patients with secondary hyperparathyroidism [intact PTH (iPTH) Results. Treatment was discontinued for various reasons in nine patients in each group, but no serious side effects were observed in either group. The numbers of cases reaching the first end point were not significantly different between the two groups. Serum calcium concentration was significantly higher in the maxacalcitol than the calcitriol group during early treatment, but not at the end of treatment. Throughout the treatment period there were no significant differences between the two groups in serum iPTH, inorganic phosphate, the product of the serum calcium and inorganic phosphorus concentrations, bAP, or the ratio of whole PTH to total PTH minus whole PTH. Nor were the changes in these parameters significantly different between the two groups comparing the patients with moderate to severe hyperparathyroidism (basal iPTH Conclusion. Calcitriol and maxacalcitol are equally effective on PTH and bone metabolism.
Accepted April 7, 2004
Original Article
Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial
2 Tsuchiya Clinic, Tokyo, Japan
3 Suimei Clinic, Tokyo, Japan
4 Kokubunnji Minamiguchi Clinic, Tokyo, Japan
5 Yoshizawa Clinic, Saitama, Japan
6 Nakamura Clinic, Kanagawa, Japan
Abstract 
150 pg/ml] to have either calcitriol (47 patients) or maxacalcitol (44 patients) therapy, for 12 months after a 1 month control period. Serum electrolytes, bone alkaline phosphatase (bAP), iPTH, total PTH and PTH(1-84) (whole PTH) levels were measured periodically. The first end point was a serum iPTH of <150 pg/ml, the second was the iPTH levels obtained.500 pg/ml).
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. C. Palmer, D. O. McGregor, P. Macaskill, J. C. Craig, G. J. Elder, and G. F.M. Strippoli Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease Ann Intern Med, December 18, 2007; 147(12): 840 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jindal, C. T. Chan, C. Deziel, D. Hirsch, S. D. Soroka, M. Tonelli, and B. F. Culleton CHAPTER 3: Mineral Metabolism J. Am. Soc. Nephrol., March 1, 2006; 17(3_suppl_1): S11 - S15. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Reichel Current treatment options in secondary renal hyperparathyroidism Nephrol. Dial. Transplant., January 1, 2006; 21(1): 23 - 28. [Full Text] [PDF]
|
|